KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EBT (2016 - 2025)

Nektar Therapeutics has reported EBT over the past 16 years, most recently at -$34.7 million for Q4 2025.

  • Quarterly results put EBT at -$34.7 million for Q4 2025, down 595.6% from a year ago — trailing twelve months through Dec 2025 was -$155.5 million (down 30.44% YoY), and the annual figure for FY2025 was -$155.5 million, down 30.44%.
  • EBT for Q4 2025 was -$34.7 million at Nektar Therapeutics, up from -$35.0 million in the prior quarter.
  • Over the last five years, EBT for NKTR hit a ceiling of $232.9 million in Q4 2023 and a floor of -$159.0 million in Q2 2022.
  • Median EBT over the past 5 years was -$51.7 million (2023), compared with a mean of -$58.3 million.
  • Biggest five-year swings in EBT: surged 511.87% in 2023 and later crashed 595.6% in 2025.
  • Nektar Therapeutics' EBT stood at -$146.8 million in 2021, then surged by 61.48% to -$56.5 million in 2022, then surged by 511.87% to $232.9 million in 2023, then crashed by 96.99% to $7.0 million in 2024, then crashed by 595.6% to -$34.7 million in 2025.
  • The last three reported values for EBT were -$34.7 million (Q4 2025), -$35.0 million (Q3 2025), and -$39.4 million (Q2 2025) per Business Quant data.